Future Healthcare Investment Market (FHIM) 2026 – Europe Meets China in Shanghai

Mark your calendars – the Future Healthcare Investment Market (FHIM) rolls into Shanghai on 4‑5 November 2026. It’s not just another trade show; it’s a tightly‑curated rendezvous where European healthcare powerhouses meet Asian investors, hospitals and innovators looking for the next big partnership.

What makes FHIM special? For starters, the procurement side is stacked with heavy‑hitters like Hirslanden, the Swiss private‑hospital group, the European Hospital Procurement Professionals Association (EHPPA), MercurHosp and the pan‑European digital GPO XMED iQ. These organisations represent everything from private‑clinic networks to public‑sector buying consortia, meaning Asian buyers can tap into a truly continent‑wide supply chain in a single conversation.

But the event isn’t just about buying equipment. Hospital administrators from across Asia will sit down with Chinese public and private hospital networks as well as their European counterparts. The agenda is deliberately broad – think clinical practice exchanges, technology roll‑outs, digital‑transformation road‑maps and, of course, long‑term partnership agreements that could reshape how patients are treated on both sides of the Silk Road.

Investors, too, get a front‑row seat. FHIM draws European limited partners, family offices, insurers and specialised healthcare funds, offering Asian general partners and limited partners a chance to co‑invest, raise capital and build enduring financing pipelines. Whether you’re hunting high‑growth pharma pipelines, med‑tech innovations or digital‑health platforms, the floor is teeming with deal‑ready projects.

Med‑tech firms will find the event especially useful. Asian companies eyeing entry into European hospital systems can connect with procurement decision‑makers, clinical validation experts and local distributors, while European innovators get a direct line to Chinese hospital networks eager for cutting‑edge devices.

Pharma and biotech players aren’t left out either. Business‑development teams from major European pharmaceutical groups will mingle with Chinese investors, clinical partners and regulatory experts – a perfect setting for licensing talks, joint‑development agreements and cross‑border commercialization strategies.

The scaffolding behind FHIM is a partnership between IPEM (International Private Equity Market), HBI (Healthcare Business International) and a deep‑rooted China‑based network that spans government bodies, leading hospitals, investors and innovation hubs. In short, the event is built on relationships, not just a booth‑rental model.

So whether you’re a hospital CIO hunting the next digital‑health platform, a venture fund looking for a European biotech gem, or a med‑tech startup yearning for a foot in the Chinese market, FHIM 2026 promises the kind of face‑to‑face interaction that can’t be replicated online.

Ready to be part of the conversation? Register now, pack your business cards and prepare for a two‑day sprint that could change the trajectory of your organization’s international growth.